BSC – active pharmaceutical ingredients (API), which are poorly soluble, but have sufficient permeability. In terms of physical state, these are amorphous powders, which are characterized by insufficient flowability. Therefore, a method of compression using wet granulation is acceptable for the manufacture of solid dosage forms of capsules and tablets, obtaining capsule mass, tablet mass.

Conclusions. Therefore, the pharmaceutical development of solid dosage forms of mono and combined drugs with pharmaceutically acceptable gliflozin derivatives is promising for the domestic pharmaceutical market.

ANALYSIS OF SCHEMES AND RECOMMENDATIONS FOR ENZYME REPLACEMENT THERAPY OF GAUCHER DISEASE IN UKRAINE

Podgaina M.V., Sliptsova N.A.
National University of Pharmacy, Kharkiv, Ukraine
economica@nuph.edu.ua

Introduction. Until recently, Gaucher disease was treated according to its symptoms: the spleen was removed or surgery was performed for pathological fractures. But three decades ago, the first medicine, aglucerase, appeared in the US and was successfully used to treat the disease.

Aim of the research is to analyze topical schemes and recommendations for therapy of gaucher disease in Ukraine. **Methods** of literature research, summarizing, generalization and content analysis were used.

Main material of the research. The main and effective method of treatment of Gaucher disease is enzyme replacement therapy, which is indicated for use as a permanent life therapy in patients with a confirmed diagnosis of Gaucher disease type I and III. In type II management of the disease is the use of symptomatic maintenance treatment. In patients with type II Gaucher disease, partial splenectomy (surgical or thromboembolism) may relieve some symptoms. For children with type III disease in

order to correct severe visceral manifestations, it is recommended to prescribe enzyme replacement therapy in a minimum dose. Gaucher disease became the first among the diseases of accumulation, which was exposed to therapy with enzyme substitutes. Later, the medicine imiglucerase (cerezim) appeared, which is an analogue of the human enzyme glucocerebrosidase, obtained using genetically engineered technology. The purpose of such treatment was to prevent irreversible damage to the musculoskeletal system and other vital organs (liver, lungs, kidneys), as well as regression or weakening of the cytopenic syndrome, reducing the size of the spleen and liver.

In Ukraine, the following regulations have been approved for the diagnosis and treatment of patients with Gaucher disease:

1. Order of the Ministry of Health of Ukraine №529 of 19.08.2015 "On approval and implementation of medical and technological documents for the standardization of medical care for Gaucher disease."

2. Unified clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical care for Gaucher disease. The order of the Ministry of Health dated 19.08.2015 №529.

3. Adapted evidence-based clinical guidelines. State Expert Center of the Ministry of Health. OKHMADIT National Children's Specialized Hospital.

4. Resolution of the Cabinet of Ministers of Ukraine of March 31, 2015 №160 “On approval of the Procedure for providing citizens suffering from rare (orphan) diseases with medicines and appropriate food products for special dietary consumption. (With changes made in accordance with the Resolution of the Cabinet of Ministers №884 of 23.09.2020).

In accordance with the current unified protocol and international protocols for the treatment of patients with Gaucher disease in Ukraine were included in the nomenclature of 2018 and the following medicines are used: Taliglucerase alpha is a recombinant analogue of human lysosomal glucocerebrosidase, which catalyzes the hydrolysis of glucocerebroside with the formation of glucose and ceramide, reducing

the amount of accumulated glucocerebroside and Velaglucerase alpha - a form of enzyme obtained on human cell lines using gene activation technology. Special social and economic positive aspect for patients is the presence of these ьувшсштуі in the lists of public procurement in 2019-2020, noting that: Velaglucerase alfa and Taliglucerase alfa can be used to treat newly diagnosed patients with Gaucher disease type I in the presence of adverse reactions to the introduction or ineffectiveness of another medicine in an adequate therapeutic dose and in accordance with the instructions for use and taking into account individual characteristics.

Conclusions. It is important to pay government attention to rare patients, especially Gaucher disease' patients, which treatment is long-life and essential for quality physical, social, mental spheres of being.

ACTUAL ISSUES OF THE DEMENTIA

Starostenko S.Yu., Starostenko V.V.
Donetsk National Medical University, Kramatorsk, Ukraine
s.starostenko@ukr.net

Introduction. Dementia is a syndrome that leads to deterioration in cognitive function beyond the biological ageing. It affects memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement. According to the World Health Organization's report, only a quarter of the world has a national policy, strategy or plan to support people with dementia and their families. Half of these countries are located in the WHO European Region and the rest in other regions.

Aim of the research is to admit the attention to the problem of dementia and appropriate management in Ukraine.

Methods of specialized literature analysis, statistic and mathematic methods were used.

Main material of the research. WHO estimates that more than 55 million people suffer from dementia (8.1% of women and 5.4% of men over the age of 65). It